靶向免疫调节：重症医学专家入门指南。 - Suppr

Suppr

超能文献

Targeted immunomodulation: a primer for intensivists.

作者信息

Janssen Malou, Endeman Henrik, Bos Lieuwe D J

机构信息

Internal Medicine, Reinier de Graaf Gasthuis, Delft, The Netherlands.

Intensive Care, Erasmus MC, Rotterdam, The Netherlands.

出版信息

Intensive Care Med. 2023 Apr;49(4):462-464. doi: 10.1007/s00134-023-07009-8. Epub 2023 Mar 3.

DOI:10.1007/s00134-023-07009-8

PMID:36867231

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9982766/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b816/10119241/f9aa2b0848d5/134_2023_7009_Fig1_HTML.jpg

相似文献

Targeted immunomodulation: a primer for intensivists.靶向免疫调节：重症医学专家入门指南。

Intensive Care Med. 2023 Apr;49(4):462-464. doi: 10.1007/s00134-023-07009-8. Epub 2023 Mar 3.

Myocarditis: a primer for intensivists.心肌炎：重症监护医师入门指南

Intensive Care Med. 2023 Sep;49(9):1123-1126. doi: 10.1007/s00134-023-07143-3. Epub 2023 Jul 10.

External Intensivists Versus In-House Intensivists.外部重症医学专家与院内重症医学专家

Mo Med. 2019 Sep-Oct;116(5):363.

Need for intensivists in intensive-care units.重症监护病房对重症医学专家的需求。

Lancet. 2000 Aug 26;356(9231):695-6. doi: 10.1016/S0140-6736(00)02622-2.

Would you like to be admitted to the ICU? The preferences of intensivists and general public according to different outcomes.你是否愿意被收入 ICU？根据不同的结局，重症监护医生和普通公众的偏好。

J Crit Care. 2019 Oct;53:193-197. doi: 10.1016/j.jcrc.2019.06.019. Epub 2019 Jun 24.

[A new challenge: the shortage of intensivists].一项新挑战：重症医学专家短缺

Medicina (B Aires). 2023;83(5):858.

Intensivists..重症监护医师

Crit Care Med. 2001 Apr;29(4):904-5. doi: 10.1097/00003246-200104000-00048.

Clinical Assessment of Intensivists: Is it Time to Introduce Actors to the ICU?重症监护医生的临床评估：是时候在重症监护病房引入演员了吗？

Crit Care Med. 2016 May;44(5):1017-8. doi: 10.1097/CCM.0000000000001690.

Are intensivists safe?重症监护医生安全吗？

Ann Intern Med. 2008 Jun 3;148(11):877-9. doi: 10.7326/0003-4819-148-11-200806030-00010.

What's behind the white coat: Potential mechanisms of physician-attributable variation in critical care.白大衣背后的原因：重症监护中医生归因差异的潜在机制。

PLoS One. 2019 May 16;14(5):e0216418. doi: 10.1371/journal.pone.0216418. eCollection 2019.

引用本文的文献

Molecular mechanisms and potential implications of ferroptosis, cuproptosis, and disulfidptosis in septic lung injury.铁死亡、铜死亡和二硫键介导的细胞死亡在脓毒症肺损伤中的分子机制及潜在影响

Front Med (Lausanne). 2025 Aug 15;12:1615264. doi: 10.3389/fmed.2025.1615264. eCollection 2025.

Immunobiological effects of tocilizumab across respiratory subphenotypes in COVID-19 ARDS.托珠单抗对新冠病毒感染所致急性呼吸窘迫综合征不同呼吸亚表型的免疫生物学效应

Intensive Care Med Exp. 2025 Jul 9;13(1):70. doi: 10.1186/s40635-025-00779-z.

Insights into sepsis-induced apoptosis: Interplay between programmed cell death and interleukin-7.脓毒症诱导的细胞凋亡研究进展：程序性细胞死亡与白细胞介素-7之间的相互作用

J Crit Care Med (Targu Mures). 2025 Apr 30;11(2):132-139. doi: 10.2478/jccm-2025-0003. eCollection 2025 Apr.

Clinical features and treatments of VEXAS syndrome in critical care: a scoping review.危重症护理中VEXAS综合征的临床特征与治疗：一项范围综述

Crit Care. 2025 Apr 17;29(1):154. doi: 10.1186/s13054-025-05390-y.

The Role of PD-1/PD-L1 and IL-7 in Lymphocyte Dynamics and Sepsis Progression: A Biomarker Study in Critically Ill Patients.PD-1/PD-L1和IL-7在淋巴细胞动态变化及脓毒症进展中的作用：一项针对危重症患者的生物标志物研究

Int J Mol Sci. 2024 Nov 24;25(23):12612. doi: 10.3390/ijms252312612.

Preclinical and first-in-human safety studies on a novel magnetism-based haemofiltration method.新型基于磁场的血液滤过方法的临床前和人体首次安全性研究。

Sci Rep. 2024 Jun 18;14(1):14077. doi: 10.1038/s41598-024-64379-9.

Pre-existing Immunocompromising Conditions and Outcomes of Acute COVID-19 Patients Admitted for Pediatric Intensive Care.患有基础免疫抑制疾病的急性 COVID-19 患儿入住儿科重症监护病房的结局。

Clin Infect Dis. 2024 Aug 16;79(2):395-404. doi: 10.1093/cid/ciae133.

本文引用的文献

Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.迈向脓毒症个体化免疫治疗：PROVIDE 随机临床试验。

Cell Rep Med. 2022 Nov 15;3(11):100817. doi: 10.1016/j.xcrm.2022.100817.

The End of "One Size Fits All" Sepsis Therapies: Toward an Individualized Approach.“一刀切”式脓毒症治疗的终结：迈向个体化治疗方法

Biomedicines. 2022 Sep 12;10(9):2260. doi: 10.3390/biomedicines10092260.

Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes.急性呼吸窘迫综合征：病因、病理生理学和表型。

Lancet. 2022 Oct 1;400(10358):1145-1156. doi: 10.1016/S0140-6736(22)01485-4. Epub 2022 Sep 4.

Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients.免疫调节和血管内皮屏障保护介导了口服伊马替尼与住院 COVID-19 患者死亡率之间的关联。

Eur Respir J. 2022 Dec 15;60(6). doi: 10.1183/13993003.00780-2022. Print 2022 Dec.

Redefining critical illness.重新定义危重症。

Nat Med. 2022 Jun;28(6):1141-1148. doi: 10.1038/s41591-022-01843-x. Epub 2022 Jun 17.

A guide to immunotherapy for COVID-19.针对 COVID-19 的免疫疗法指南。

Nat Med. 2022 Jan;28(1):39-50. doi: 10.1038/s41591-021-01643-9. Epub 2022 Jan 21.

Biological Subphenotypes of Acute Respiratory Distress Syndrome Show Prognostic Enrichment in Mechanically Ventilated Patients without Acute Respiratory Distress Syndrome.急性呼吸窘迫综合征的生物学亚表型在未患有急性呼吸窘迫综合征的机械通气患者中具有预后优势。

Am J Respir Crit Care Med. 2021 Jun 15;203(12):1503-1511. doi: 10.1164/rccm.202006-2522OC.

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者

N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.

Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs.明智之战：炎症性风湿性疾病中的免疫抑制与免疫调节

Ann Rheum Dis. 2020 Aug;79(8):991-993. doi: 10.1136/annrheumdis-2020-218019. Epub 2020 Jun 11.

Advances in the understanding and treatment of sepsis-induced immunosuppression.脓毒症导致免疫抑制的研究进展及治疗策略。

Nat Rev Nephrol. 2018 Feb;14(2):121-137. doi: 10.1038/nrneph.2017.165. Epub 2017 Dec 11.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验